Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968553 | 0.94 | S1PR5 (0.35) | S1PR5S1PR1S1PR3TLR9TLR8 | |
| SCHEMBL15968237 | 0.91 | GRM2 (0.36) | ACACBGRM2 | |
| SCHEMBL15969123 | 0.88 | S1PR5 (0.40) | S1PR5S1PR1S1PR3TLR9TLR8 | |
| SCHEMBL15968161 | 0.85 | GRM2 (0.36) | ACACBGRM2 | |
| SCHEMBL15968153 | 0.83 | ACACB (0.47) | ACACB | |
| SCHEMBL15968096 | 0.81 | S1PR5 (0.38) | S1PR5S1PR1S1PR3TLR9TLR8 | |
| SCHEMBL15968677 | 0.79 | KMO (0.40) | S1PR5S1PR1ACACBGRM2 | |
| SCHEMBL15969110 | 0.77 | S1PR5 (0.40) | S1PR5S1PR1S1PR3TLR9TLR8 | |
| SCHEMBL15968752 | 0.76 | ACACB (0.48) | ACACB | |
| SCHEMBL15968769 | 0.75 | CCNT1 (0.41) | S1PR5S1PR1S1PR3GRM2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | S1PR5 1924/4885S1PR1 2272/4885S1PR3 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.